Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Matrix III Cisplatin
- Development stage
- Preclinical
- Lead developer
- Royer Biomedical
- Modality
- Small Molecules, Drug Delivery Systems
- Administration
- Localized, Matrix Implantation
01
Overview
Matrix III Cisplatin is a localized, controlled-release drug delivery platform developed by Royer Biomedical for the treatment of equine sarcoids. It utilizes a proprietary calcium-based matrix (Matrix III technology) to deliver cisplatin, a platinum-based cytotoxic chemotherapy agent that acts as a DNA crosslinker. The formulation consists of biodegradable beads designed for local implantation or application directly at the tumor site, typically following surgical debulking of lesions up to 3 cm in diameter. This delivery method is intended to concentrate the therapeutic agent at the site of the lesion while minimizing systemic exposure and associated toxicity. The product has received Minor Use/Minor Species (MUMS) designation from the FDA Center for Veterinary Medicine.
- Brand names
- Matrix III Cisplatin
- Other names
- cisplatin
02
Targets
DNA
Beyond the preview
Go deeper on Matrix III Cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Matrix III Cisplatin.